Blb&b Advisors buys $8,320,095 stake in Pfizer (PFE)

Pfizer (PFE) : Blb&b Advisors scooped up 10,307 additional shares in Pfizer during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 18, 2016. The investment management firm now holds a total of 250,078 shares of Pfizer which is valued at $8,320,095.Pfizer makes up approximately 1.65% of Blb&b Advisors’s portfolio.

Pfizer opened for trading at $33.25 and hit $33.5 on the upside on Friday, eventually ending the session at $33.27, with a gain of 0.09% or 0.03 points. The heightened volatility saw the trading volume jump to 2,61,37,321 shares. Company has a market cap of $205,746 M.

Other Hedge Funds, Including , Murphy Capital Management Inc boosted its stake in PFE in the latest quarter, The investment management firm added 3,484 additional shares and now holds a total of 64,447 shares of Pfizer which is valued at $2,144,152. Pfizer makes up approx 0.33% of Murphy Capital Management Inc’s portfolio.Financial Investment Management Group Ltd boosted its stake in PFE in the latest quarter, The investment management firm added 429 additional shares and now holds a total of 8,280 shares of Pfizer which is valued at $269,100. Pfizer makes up approx 0.07% of Financial Investment Management Group Ltd’s portfolio.Beese Fulmer Investment Management reduced its stake in PFE by selling 983 shares or 1.67% in the most recent quarter. The Hedge Fund company now holds 57,998 shares of PFE which is valued at $1,884,935. Pfizer makes up approx 0.54% of Beese Fulmer Investment Management’s portfolio.New England Research Management boosted its stake in PFE in the latest quarter, The investment management firm added 2,650 additional shares and now holds a total of 46,210 shares of Pfizer which is valued at $1,473,637. Pfizer makes up approx 1.27% of New England Research Management’s portfolio.

On the company’s financial health, Pfizer reported $0.53 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $0.36. The company had revenue of $14047.00 million for the quarter, compared to analysts expectations of $13595.19 million. The company’s revenue was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.54 EPS.

Many Wall Street Analysts have commented on Pfizer. Goldman Resumed Pfizer on Apr 18, 2016 to “Neutral”, Price Target of the shares are set at $35.JP Morgan Resumed Pfizer on Apr 7, 2016 to “Overweight”, Price Target of the shares are set at $38.Morgan Stanley Resumed Pfizer on Apr 7, 2016 to “Equal-Weight”, Price Target of the shares are set at $35.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Leave a Reply

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.